2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. SWI/SNF Complex
  5. SMARCA4 Isoform

SMARCA4

BRG1, BAF190A

SMARCA4 (also known as BRG1) encodes the ATPase catalytic subunit of the SWI/SNF chromatin-remodeling complex and uses ATP hydrolysis to alter nucleosome positioning, thereby regulating chromatin accessibility and transcriptional programs[1][2]. Mechanistically, SMARCA4 functions as a core epigenetic regulator that coordinates gene expression, DNA damage-associated chromatin responses, and cell-state transitions through ATP-dependent chromatin remodeling[1][3]. As one of two mutually exclusive SWI/SNF ATPase subunits, SMARCA4 is functionally distinct from SMARCA2 (BRM), with each complex containing either BRG1 or BRM as its catalytic engine rather than both simultaneously[4][5]. This isoform distinction is biologically important because SMARCA4 deficiency can increase cellular dependence on SMARCA2-containing SWI/SNF complexes in specific tumor contexts[4][6]. In disease settings, recurrent SMARCA4 inactivation has been identified across multiple malignancies and is strongly associated with chromatin dysregulation, including small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), where loss of SMARCA4 protein is a defining molecular feature[4][6][7]. Experimental studies further demonstrate that restoration of either SMARCA4 or SMARCA2 suppresses growth of SMARCA4-deficient SCCOHT cell lines, supporting a tumor-suppressive role for SWI/SNF ATPase activity in this model[4]. For experimental applications, the SMARCA4 bromodomain recognizes acetylated histone H3K14 and has therefore emerged as a potential target for developing bromodomain-directed chemical probes and inhibitors that interrogate chromatin-remodeling mechanisms in cancer and epigenetic research[3].

SMARCA4 Related Products (11):

Cat. No. Product Name Effect Purity
  • HY-145388
    AU-15330
    		Degrader 99.89%
    AU-15330 is a proteolysis-targeting chimera (PROTAC) degrader of the SWI/SNF ATPase subunits, SMARCA2 and SMARCA4. AU-15330 induces potent inhibition of tumour growth in xenograft models of prostate cancer and synergizes with the AR antagonist enzalutamide. AU-15330 induces disease remission in castration-resistant prostate cancer (CRPC) models without toxicity.
  • HY-128359
    ACBI1
    		Degrader 99.92%
    ACBI1 is a potent and cooperative SMARCA2, SMARCA4 and PBRM1 degrader with DC50s of 6, 11 and 32 nM, respectively. ACBI1 is a PROTAC degrader. ACBI1 shows anti-proliferative activity. ACBI1 induces apoptosis.
  • HY-159607
    PRT3789
    		Degrader 98.08%
    PRT3789 is a selective SMARCA2 PROTAC degrader (DC50 in HeLa cell: 0.72 nM for SMARCA2, 14 nM for SMARCA4). PRT3789 forms a stable ternary complex with Von Hippel-Lindau (VHL) E3 ligase, induces polyubiquitination at SMARCA2-specific lysine residues, and drives proteasome-dependent SMARCA2 degradation. PRT3789 disrupts SWI/SNF chromatin remodeling complex integrity, induces dissociation of specific subunits, suppresses oncogenic gene expression, reduces chromatin accessibility, and upregulates antigen processing/presentation-related gene expression. PRT3789 induces synthetic lethality, inhibits proliferation and colony formation, and drives tumor growth inhibition and regression in SMARCA4-deficient contexts. PRT3789 can be used for the research of SMARCA4-mutated solid tumors, non-small cell lung cancer, endometrial cancer, colorectal cancer, bladder cancer, esophageal cancer, ovarian cancer, and gastric cancer.
  • HY-44012
    SMARCA-BD ligand 1 for PROTAC
    		Ligand 99.07%
    SMARCA-BD ligand 1 for PROTAC is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • HY-44012B
    SMARCA-BD ligand 1 for PROTAC hydrochloride
    		Ligand 99.24%
    SMARCA-BD ligand 1 hydrochloride for PROTAC is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • HY-185075
    FHD-909
    		Inhibitor
    FHD-909 (LY4050784) is an orally active and selective SMARCA2 (BRM) ATPase inhibitor. FHD-909 potently inhibits purified BRM ATPase with an IC50 of 0.0025 μM and exhibits 35.69-fold selectivity for BRM over purified SMARCA4 (BRG1) ATPase. FHD-909 induces synthetic lethality, suppresses cell proliferation, modulates target gene expression, and achieves remarkable tumor growth inhibition and regression in SMARCA4-mutant cancer cells and xenograft models. FHD-909 can be used for the research of SMARCA4/BRG1-mutant cancers, advanced solid tumors, and BAF complex-related disorders.
  • HY-44012A
    SMARCA-BD ligand 1 for PROTAC dihydrochloride
    		Ligand 98.08%
    SMARCA-BD ligand 1 for PROTAC dihydrochloride is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
  • HY-171765
    SMARCA2/4-ligand-6
    		Ligand
    SMARCA2/4-ligand-6 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). SMARCA2/4-ligand-6 can be used for the synthesis of SMD-3040 (HY-156568).
  • HY-161885
    SMARCA2/4-IN-4
    		Inhibitor
    SMARCA2-IN-6 is a SMARCA2 and SMARCA4 inhibitor, with an IC50 value of <0.005 μM for both SMARCA2 and SMARCA4. SMARCA2-IN-6 exerts anticancer activity against BRG1-mutant melanoma. SMARCA2-IN-6 can be used for research related to Brg1/Smarca4-mutant cancers.
  • HY-170817
    SMI-1074
    		Inhibitor
    SMI-1074, a SMARCA bromodomain inhibitor, is a PROTAC target protein ligand (Ligand for Target Protein for PROTAC). SMI-1074 can be used for synthesis SMD-3236 (HY-170824) and SMD-1087 (HY-170828). SMI-1074 can be used for the research of smarca4-deficient cancers.
  • HY-159472
    SMARCA2/4-ligand-1
    		Inhibitor
    2-(6-Amino-5-(1-(piperidin-4-ylmethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)phenol is a Ligand for target protein for pROTAC.